# US 2025/0084482 A1 · Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084482 A1
- Document ID: US20250084482A1
- Status: Published application
- Kind: A1
- Application number: 18/570,006
- Filed: 2022-06-24
- Published: 2025-03-13
- Earliest claimed: 2021-06-25
- Assignees: Foundation Medicine, Inc.
- Applicants: Foundation Medicine, Inc.
- Inventors: Meagan Kathleen MONTESION; Lee Alan ALBACKER; Karthikeyan MURUGESAN
- Web page: https://patentgrep.com/patent/US20250084482A1

## CPC

- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Provided herein are methods related to detecting loss of heterozygosity (LOH) of one or more human leukocyte antigen (HLA) genes and/or tumor mutational burden (TMB), as well as methods of treatment and uses related thereto. Detection of LOH of one or more HLA genes and/or TMB can be used to identify individuals that may benefit from treatment with an immune checkpoint inhibitor.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

A method of treating or delaying progression of a squamous cell cancer or a NSCLC, comprising:
(a) acquiring knowledge of:
(i) a somatic LOH of one or more HLA-I genes, or
(ii) a somatic LOH of one or more HLA-I genes and a high TMB,
in a sample from an individual having a squamous cell cancer or a NSCLC; and
(b) responsive to said knowledge, administering to the individual an effective amount of a treatment that comprises an immune checkpoint inhibitor.

### Claim 10

A method of treating or delaying progression of a squamous cell cancer or a NSCLC, comprising,
responsive to acquiring knowledge of:
(i) a somatic LOH of one or more HLA-I genes, or
(ii) a somatic LOH of one or more HLA-I genes and a high TMB,
in a sample from an individual having a squamous cell cancer or a NSCLC,
administering to the individual an effective amount of a treatment that comprises an immune checkpoint inhibitor.

### Claim 11

(canceled)

### Claim 12

A method of treating or delaying progression of a squamous cell cancer or a NSCLC, comprising:
(a) detecting in a sample from an individual having a squamous cell cancer or a NSCLC:
(i) a somatic LOH of one or more HLA-I genes, or
(ii) a somatic LOH of one or more HLA-I genes and a high TMB; and
(b) administering to the individual an effective amount of a treatment that comprises an immune checkpoint inhibitor.

### Claim at position 6

13-14. (canceled)

### Claim 15 (depends on 12)

The method of claim 12, wherein detecting somatic LOH of one or more HLA-I genes comprises:
providing a plurality of nucleic acids obtained from a sample from the individual, wherein the plurality of nucleic acids comprises nucleic acids encoding an HLA-I gene;
optionally, ligating one or more adaptors onto one or more nucleic acids from the plurality of nucleic acids;
amplifying nucleic acids from the plurality of nucleic acids;
capturing a plurality of nucleic acids corresponding to the HLA-I gene, wherein the plurality of nucleic acids corresponding to the HLA-I gene is captured from the amplified nucleic acids by hybridization with a bait molecule;
sequencing, by a sequencer, the captured nucleic acids to obtain a plurality of sequence reads corresponding to the HLA-I gene;
fitting, by one or more processors, one or more values associated with one or more of the plurality of sequence reads to a model; and
based on the model, detecting the somatic LOH of one or more HLA-I genes and a relative binding propensity for an HLA allele of the HLA-I gene.

### Claim 16

(canceled)

### Claim 17 (depends on 12)

The method of claim 12, wherein detecting somatic LOH of one or more HLA-I genes comprises determining the specific copy number of an HLA allele of the one or more HLA-I genes in the squamous cell cancer or NSCLC.

### Claim at position 10

18-20. (canceled)

### Claim 21 (depends on 12)

The method of claim 12, wherein somatic LOH of one or more HLA-I genes is detected by whole exome sequencing, whole genome sequencing, gene-targeted sequencing, or next-generation sequencing.

### Claim at position 12

22-24. (canceled)

### Claim 25 (depends on 12)

The method of claim 12, wherein a high TMB comprises a TMB of at least about 10 mutations/megabase (mut/Mb).

### Claim 26

(canceled)

### Claim 27 (depends on 12)

The method of claim 12, wherein the squamous cell cancer or NSCLC is PD-L1-positive.

### Claim at position 16

28-31. (canceled)

### Claim 32 (depends on 12)

The method of claim 12, wherein the squamous cell cancer or NSCLC has a tumor mutational burden of at least about 10 mut/Mb.

### Claim 33 (depends on 12)

The method of claim 12, wherein:
(a) the squamous cell cancer or NSCLC does not comprise a mutation in an EGFR gene and/or an ALK gene;
(b) the squamous cell cancer or NSCLC is EGFR-wild type and/or ALK-wild type; or
(c) the squamous cell cancer or NSCLC does not comprise a pathogenic mutation in an EGFR gene and/or an ALK gene.

### Claim at position 19

34-35. (canceled)

### Claim 36 (depends on 12)

The method of claim 12, wherein the squamous cell cancer or NSCLC is an advanced and/or metastatic squamous cell cancer or NSCLC.

### Claim at position 21

37-39. (canceled)

### Claim 40 (depends on 12)

The method of claim 12, wherein the squamous cell cancer is a skin, lip, mouth, esophageal, head and neck, urinary tract, thyroid, penis, prostate, bladder, lung, vaginal, or cervical cancer.

### Claim at position 23

41-43. (canceled)

### Claim 44 (depends on 40)

The method of claim 40, wherein the squamous cell cancer is a squamous cell lung cancer.

### Claim 45 (depends on 44)

The method of claim 44, wherein:
(a) the squamous cell lung cancer comprises a mutation in a CDKN2A gene, a SOX2 gene, an LRP1B gene, a BRCA1 gene, an FGF12 gene, a TERC gene, a PIK3CA gene, a PRKCI gene, a PTEN gene, an ARID1A gene, a KDM5A gene, a SPTA1 gene, a FAS gene, an FUBP1 gene, or any combination thereof;
(b) the squamous cell lung cancer comprises a tobacco signature; and/or
(c) the squamous cell lung cancer is a non-small cell lung cancer (NSCLC).

### Claim at position 26

46-47. (canceled)

### Claim 48 (depends on 12)

The method of claim 12, wherein:
(a) the squamous cell cancer or NSCLC was previously treated with an immune checkpoint inhibitor;
(b) the squamous cell cancer or NSCLC was previously treated with an anti-cancer therapy other than an immune checkpoint inhibitor;
(c) the squamous cell cancer or NSCLC was not previously treated with an immune checkpoint inhibitor;
(d) the squamous cell cancer or NSCLC was not previously treated with an anti-cancer therapy other than an immune checkpoint inhibitor;
(e) the squamous cell cancer or NSCLC was not previously treated;
(f) the squamous cell cancer or NSCLC was previously treated with a first line anti-cancer therapy for squamous cell cancer or NSCLC;
(g) the squamous cell cancer or NSCLC was previously treated with a second line anti-cancer therapy for squamous cell cancer or NSCLC;
(h) the squamous cell cancer or NSCLC was previously treated with a first line immune checkpoint inhibitor for squamous cell cancer or NSCLC: or
(i) the squamous cell cancer or NSCLC was previously treated with a second line immune checkpoint inhibitor for squamous cell cancer or NSCLC.

### Claim at position 28

49-57. (canceled)

### Claim 58 (depends on 12)

The method of claim 12, wherein the immune checkpoint inhibitor is:
(a) a monotherapy;
(b) a first line immune checkpoint inhibitor;
(c) a second line immune checkpoint inhibitor; and/or
(d) a PD-1- or a PD-L1-targeted agent or a CTLA-4 inhibitor.

### Claim at position 30

59-71. (canceled)

### Claim 72 (depends on 12)

The method of claim 12, wherein the sample is obtained from the squamous cell cancer or NSCLC.

### Claim 73 (depends on 72)

The method of claim 72, wherein the sample comprises cells from the squamous cell cancer or NSCLC and/or nucleic acids from the squamous cell cancer or NSCLC.

### Claim 74 (depends on 73)

The method of claim 73, wherein:
(a) the sample further comprises non-squamous cell cancer or non-NSCLC cells and/or non-squamous cell cancer or non-NSCLC nucleic acids;
(b) the sample is from a tumor biopsy, tumor specimen, or circulating tumor cell;
(c) the sample comprises cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) from the squamous cell cancer or NSCLC;
(d) the sample comprises fluid, cells, or tissue;
(e) the sample comprises blood or plasma; or
(f) the sample is a nucleic acid sample comprising mRNA, DNA, circulating tumor DNA, cell-free DNA, or cell-free RNA.

### Claim at position 34

75-80. (canceled)

### Claim 81 (depends on 12)

The method of claim 12, wherein the individual is a human.

### Claim at position 36

82-99. (canceled)
